U-90042, a sedative/hypnotic compound that interacts differentially with the GABAA receptor subtypes

AH Tang, MW Smith, DB Carter, WB Im and PF VonVoigtlander

Upjohn Company, Kalamazoo, Michigan, USA.

U-90042 is a structurally novel compound that has comparable affinities for binding to three recombinant subtypes of the gamma-aminobutyric acidA receptor: alpha 1 beta 2 gamma 2, alpha 3 beta 2 gamma 2 and alpha 6 beta 2 gamma 2. The relatively high affinity for the alpha 6 beta 2 gamma 2 subtype is similar to the benzodiazepine (BZ) partial inverse agonist Ro 15-4513 and different from BZ sedative/hypnotics such as diazepam and zolpidem. In the present study, U-90042 (3 mg/kg i.p.) suppressed locomotor activity and impaired rotarod performance in mice. These effects were not antagonized by flumazenil. The sedative effect was further confirmed in rats (10 mg/kg i.p.) and monkeys (1 mg/kg p.o.) by an increase of behavioral sleep and a corresponding electroencephalographic frequency spectral shift. Unlike the BZ hypnotics, U-90042 (10 mg/kg i.p.) produced no amnesia in the one-trial passive avoidance response in mice but antagonized diazepam-induced amnesia. In rats trained to discriminate an injection of diazepam from saline, U-90042 produced predominantly vehicle-appropriate responses, even at depressant doses. The in vivo diazepam-antagonist effect of U- 90042 is consistent with its low intrinsic activity and diazepam- antagonism at the gamma-aminobutyric acidA alpha 1 beta 2 gamma 2 and alpha 3 beta 2 gamma 2 receptor subtypes. The receptor mechanism for the sedative/hypnotic effect is not clear at this time.

Volume 275, Issue 2, pp. 761-767, 11/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				L. R Rappa, M. Larose-Pierre, D. R Payne, N. E Eraikhuemen, D. M Lanes, and M. L Kearson Detoxification from High-Dose Zolpidem Using Diazepam Ann. Pharmacother., April 1, 2004; 38(4): 590 - 594. [Abstract] [Full Text] [PDF]